Locally Advanced/Metastatic Solid Tumors
8
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Study of ESG406 in Adults With Solid Tumors
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors